nach oben

Erschienen in:

11.10.2015 | Interventional

Predictive factors for complete response of chemoembolization with drug-eluting beads (DEB-TACE) for hepatocellular carcinoma

verfasst von: Guillaume Vesselle, Camille Quirier-Leleu, Stéphane Velasco, Florian Charier, Christine Silvain, Samy Boucebci, Pierre Ingrand, Jean-Pierre Tasu

Erschienen in: European Radiology | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To identify clinical and imaging features associated with complete response (CR) to first session of transarterial chemoembolization (TACE) with drug-eluting beads (DEB) in patients with hepatocellular carcinoma.

Methods

In this prospective historical cohort, 172 patients with 315 tumours who received at least one DEB-TACE from 2007 to 2013 were studied. Imaging response was evaluated according to the modified Response Evaluation Criteria in Solid Tumours (mRECIST). Age, gender, aetiology of cirrhosis, Child and BCLC scores, particles size, location in the liver, size of the tumour, presence of a capsule, hypervascularisation on DSA and CT/MRI scans, and blush extinction were analysed.

Results

After one session of treatment, CR was observed in 36 % of the 315 tumours treated. Nodule size, location in the liver, and complete blush extinction on DSA was statistically correlated to complete response, whereas capsule aspect on imaging and demographic criteria were not. In multivariate analysis only, location in the liver and nodule size were significant features.

Conclusions

Tumour location in the segments 1 and 4 is a pejorative factor for CR, whereas tumour size <5 cm is a positive predictive factor. These criteria could, therefore, be taken into consideration to improve the selection of patients for DEB-TACE.

Key Points

• Literature on predictive factors of complete response after DEB-TACE is under-studied.

• Tumour size <5 cm is associated with complete response.

• Location in segments 1 or 4 is a pejorative factor for response.

• No demographic parameter influences complete response.

Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A et al (2010) Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study. Cardiovasc Intervent Radiol 33:41–52CrossRefPubMedPubMedCentral

Malagari K, Pomoni M, Kelekis A et al (2010) Prospective Randomized Comparison of Chemoembolization with Doxorubicin-Eluting Beads and Bland Embolization with BeadBlock for Hepatocellular Carcinoma. Cardiovasc Intervent Radiol 33:541–51CrossRefPubMed

Song MJ, Chun HJ, Song DS et al (2012) Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol 57:1244–50CrossRefPubMed

Varela M, Real MI, Burrel M et al (2007) Chemoembolization of hepatocellular carcinoma with drug eluting beads: Efficacy and doxorubicin pharmacokinetics. J Hepatol 46:474–81CrossRefPubMed

Lewis AL, Gonzalez MV, Lloyd AW et al (2006) DC Bead: In Vitro Characterization of a Drug-delivery Device for Transarterial Chemoembolization. J Vasc Interv Radiol 17:335–42CrossRefPubMed

Kettenbach J, Stadler A, Katzler IV et al (2008) Drug-Loaded Microspheres for the Treatment of Liver Cancer: Review of Current Results. Cardiovasc Intervent Radiol 31:468–76

Huang K, Zhou Q, Wang R, Cheng D, Ma Y (2014) Doxorubicin-eluting Bead versus Conventional Transarterial Chemoembolization for the Treatment of HCC: a Meta-Analysis. J Gastroenterol Hepatol 29(5):920–925

European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer (2012) EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 56:908–43CrossRef

Bruix J, Sherman M (2011) Management of hepatocellular carcinoma: An update. Hepatology 53:1020–2CrossRefPubMedPubMedCentral

10.

Raoul J-L, Sangro B, Forner A et al (2011) Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev 37:212–20CrossRefPubMed

11.

Bolondi L, Burroughs A, Dufour J-F et al (2013) Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions. Semin Liver Dis 32:348–59CrossRef

12.

D’Avola D, Iñarrairaegui M, Pardo F et al (2011) Prognosis of Hepatocellular Carcinoma in Relation to Treatment Across BCLC Stages. Ann Surg Oncol 18:1964–71CrossRefPubMed

13.

Memon K, Kulik L, Lewandowski RJ et al (2011) Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology 141:526–35, 535.e1–2 CrossRefPubMedPubMedCentral

14.

Kim DY, Ryu HJ, Choi JY et al (2012) Radiological response predicts survival following transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma. Aliment Pharmacol Ther 35:1343–50CrossRefPubMed

15.

Georgiades C, Geschwind J-F, Harrison N et al (2012) Lack of Response after Initial Chemoembolization for Hepatocellular Carcinoma: Does It Predict Failure of Subsequent Treatment? Radiology 265:115–23CrossRefPubMedPubMedCentral

16.

Choi J, Shim JH, Shin YM, Kim KM, Lim Y-S, Lee HC (2014) Clinical significance of the best response during repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma. J Hepatol 60:1212–8CrossRefPubMed

17.

Memon K, Kulik L, Lewandowski RJ et al (2012) Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: A subgroup analysis. J Hepatol 56:1112–20CrossRefPubMedPubMedCentral

18.

Prajapati HJ, Spivey JR, Hanish SI et al (2013) mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE). Ann Oncol 24:965–73CrossRefPubMed

19.

Malagari K, Pomoni M, Moschouris H et al (2012) Chemoembolization With Doxorubicin-Eluting Beads for Unresectable Hepatocellular Carcinoma: Five-Year Survival Analysis. Cardiovasc Intervent Radiol 35:1119–28CrossRefPubMed

20.

Odisio BC, Galastri F, Avritscher R et al. (2014) Hepatocellular Carcinomas within the Milan Criteria: Predictors of Histologic Necrosis after Drug-eluting Beads Transarterial Chemoembolization. Cardiovasc Intervent Radiol 37(4):1018-1026

21.

Golfieri R, Cappelli A, Cucchetti A et al (2011) Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small (<5 cm) hepatocellular carcinomas. Hepatology 53:1580–9CrossRefPubMed

22.

Kwan SW, Fidelman N, Ma E, Kerlan RK, Yao FY (2012) Imaging predictors of the response to transarterial chemoembolization in patients with hepatocellular carcinoma: a radiological-pathological correlation. Liver Transplant 18:727–36CrossRef

23.

Riaz A, Lewandowski RJ, Kulik L et al (2010) Radiologic–Pathologic Correlation of Hepatocellular Carcinoma Treated with Chemoembolization. Cardiovasc Intervent Radiol 33:1143–52CrossRefPubMedPubMedCentral

24.

Bryant MK, Dorn DP, Zarzour J et al (2014) Computed tomography predictors of hepatocellular carcinoma tumour necrosis after chemoembolization. HPB 16:327–35CrossRefPubMedPubMedCentral

25.

Shim JH, Kim KM, Lee Y-J et al (2010) Complete Necrosis After Transarterial Chemoembolization Could Predict Prolonged Survival in Patients with Recurrent Intrahepatic Hepatocellular Carcinoma After Curative Resection. Ann Surg Oncol 17:869–77CrossRefPubMed

26.

Lee M-Y, Chuang VP, Wei C-J, Cheng T-Y, Cherng M-T (2012) Histopathologic correlation of hepatocellular carcinoma after transcatheter arterial chemoembolization with polyvinyl alcohol particle of various sizes. Eur J Radiol 81:1976–9CrossRefPubMed

27.

Hu HT, Kim JH, Lee L-S et al (2011) Chemoembolization for Hepatocellular Carcinoma: Multivariate Analysis of Predicting Factors for Tumor Response and Survival in a 362-Patient Cohort. J Vasc Interv Radiol 22:917–23CrossRefPubMed

28.

Hayakawa K, Tanikake M, Kirishima T, Yoshinami N, Shintani H, Yamamoto E et al (2014) The incidence of contrast-induced nephropathy (CIN) following transarterial chemoembolisation (TACE) in patients with hepatocellular carcinoma (HCC). Eur Radiol 24:1105–11CrossRefPubMed

29.

Lencioni R, Llovet J (2010) Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma. Semin Liver Dis 30:052–60CrossRef

30.

Gillmore R, Stuart S, Kirkwood A et al (2011) EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol 55:1309–16CrossRefPubMed

31.

Miyayama S, Yamashiro M, Hattori Y et al (2011) Angiographic evaluation of feeding arteries of hepatocellular carcinoma in the caudate lobe of the liver. Cardiovasc Intervent Radiol 34:1244–53CrossRefPubMed

32.

Redman HC, Reuter SR (1970) Arterial Collaterals in the Liver Hilus. Radiology 94:575–9CrossRefPubMed

33.

Abdelmaksoud MHK, Louie JD, Kothary N et al (2011) Embolization of parasitized extrahepatic arteries to reestablish intrahepatic arterial supply to tumors before yttrium-90 radioembolization. J Vasc Interv Radiol 22:1355–62CrossRefPubMed

34.

Tohma T, Cho A, Okazumi S et al (2005) Communicating arcade between the right and left hepatic arteries: evaluation with CT and angiography during temporary balloon occlusion of the right or left hepatic artery. Radiology 237:361–5CrossRefPubMed

35.

Loffroy R, Lin M, Yenokyan G et al (2013) Intraprocedural C-arm dual-phase cone-beam CT: can it be used to predict short-term response to TACE with drug-eluting beads in patients with hepatocellular carcinoma? Radiology 266:636–48CrossRefPubMedPubMedCentral

36.

Choi SJ, Kim J, Seo J, Kim HS, Lee J, Park H (2015) Parametric response mapping of dynamic CT for predicting intrahepatic recurrence of hepatocellular carcinoma after conventional transcatheter arterial chemoembolization. Eur Radiol 20:1–10

37.

Yeo DM, Choi J-I, Lee YJ, Park MY, Chun HJ, Lee HG (2014) Comparison of RECIST, mRECIST, and choi criteria for early response evaluation of hepatocellular carcinoma after transarterial chemoembolization using drug-eluting beads. J Comput Assist Tomogr 38:391–7CrossRefPubMed

38.

Lewandowski RJ, Wang D, Gehl J et al (2007) A Comparison of Chemoembolization Endpoints Using Angiographic versus Transcatheter Intraarterial Perfusion/MR Imaging Monitoring. J Vasc Interv Radiol 18:1249–57CrossRefPubMed

39.

Lewis AL, Taylor RR, Hall B, Gonzalez MV, Willis SL, Stratford PW (2006) Pharmacokinetic and Safety Study of Doxorubicin-eluting Beads in a Porcine Model of Hepatic Arterial Embolization. J Vasc Interv Radiol 17:1335–43CrossRefPubMed

40.

Lee K-H, Liapi E, Vossen JA et al (2008) Distribution of Iron Oxide–containing Embosphere Particles after Transcatheter Arterial Embolization in an Animal Model of Liver Cancer: Evaluation with MR Imaging and Implication for Therapy. J Vasc Interv Radiol 19:1490–6CrossRefPubMedPubMedCentral

Titel: Predictive factors for complete response of chemoembolization with drug-eluting beads (DEB-TACE) for hepatocellular carcinoma
verfasst von: Guillaume Vesselle
Camille Quirier-Leleu
Stéphane Velasco
Florian Charier
Christine Silvain
Samy Boucebci
Pierre Ingrand
Jean-Pierre Tasu
Publikationsdatum: 11.10.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: European Radiology / Ausgabe 6/2016
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-015-3982-y

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Predictive factors for complete response of chemoembolization with drug-eluting beads (DEB-TACE) for hepatocellular carcinoma